References
- Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID: 20414205; http://dx.doi.org/10.1038/nri2744
- Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42; PMID: 15226177; http://dx.doi.org/10.1182/blood-2004-03-1110
- Abès R, Gélizé E, Fridman W H, Teillaud J-L. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010; 116:926-34; PMID: 20439625; http://dx.doi.org/10.1182/blood-2009-10-248609
- Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18:160-70; PMID: 20708157; http://dx.doi.org/10.1016/j.ccr.2010.06.014
- Selenko N, Majdic O, Jäger U, Sillaber C, Stöckl J, Knapp W. Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22:124-30; PMID: 12078853; http://dx.doi.org/10.1023/A:1015463811683
- Srivastava RM, Lee SC, Filho PAA, Lord CA, Jie H-B, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res Off J A. Assoc Cancer Res 2013; 19:1858-72; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426
- Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher Jr RJ, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a ‘vaccinal effect’ of rituximab. Blood 2009; 113:3809–12; PMID: 19196657; http://dx.doi.org/10.1182/blood-2008-10-185280
- Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014. http://dx.doi.org/10.1172/JCI73014
- Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011; 117:2423-32; PMID: 21193697; http://dx.doi.org/10.1182/blood-2010-08-301945
- Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng W-K, Clarke MF, Carlson RW, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012; 122:1066-ndash;75; PMID: 22326955; http://dx.doi.org/10.1172/JCI61226